Depo-Provera Litigation · Case Reviews Now Open
Women Who Used Depo-Provera and Were Later Diagnosed With a Meningioma May Qualify for Compensation
In December 2025 the FDA updated the Depo-Provera label to warn about meningioma, a type of brain tumor. Thousands of lawsuits are moving forward in federal court. Find out in about 60 seconds if you may qualify for a free and confidential case review.
Free review. No obligation. Your information stays confidential.
Did you or a loved one receive Depo-Provera or Depo-SubQ Provera birth control injections?
Your answers are confidential.
How it works
Answer a few questions
Takes about 60 seconds on your phone.
Speak with a case specialist for free
A short, private call to review the details.
A law firm reviews your potential claim
If your case fits, they explain your options.
Participating law firms work on a contingency basis. You pay nothing unless compensation is recovered.
About the litigation
A 2024 study published in The BMJ reported an increased risk of meningioma associated with long-term use of medroxyprogesterone acetate, the active ingredient in Depo-Provera.
In December 2025 the FDA approved updated labeling for Depo-Provera that warns about meningioma and advises monitoring.
Federal lawsuits have been consolidated in multidistrict litigation (MDL 3140) in the Northern District of Florida.
Cases are reviewed individually. Filing deadlines vary by state, which is why acting promptly matters.